A single combination gene therapy treats multiple age-related diseases.
Level 5 - mechanism / opinion, no new human data
Preclinical animal study with no human data
PubMed 31685628 · doi:10.1073/pnas.1910073116
What was done
Researchers developed adeno-associated virus gene therapies based on three longevity-associated genes (FGF21, αKlotho, and sTGFβR2) and administered them individually and in combination as a single dose in disease-specific mouse models of obesity, type II diabetes (high-fat diet), heart failure (ascending aortic constriction), and renal failure (unilateral ureteral obstruction).
What was found
A single combination formulation combining two therapies treated all four diseases. Reported outcomes included a 58% increase in heart function in heart failure, a 38% reduction in α-smooth muscle actin expression and a 75% reduction in renal medullary atrophy in renal obstruction, and complete reversal of obesity and diabetes phenotypes in high-fat diet-fed mice.
Why it matters
This study provides proof-of-concept that a single combination gene therapy can simultaneously treat multiple age-related chronic conditions rather than targeting each pathology individually.
Limits
The study was conducted entirely in mouse models, which may not replicate human pathophysiology. The abstract does not report sample sizes, specific treatment doses, long-term durability, or adverse effects and immune responses to viral vectors.
Cited by
- supports George Church's lab conducted an AAV gene therapy study in mice delivering soluble factors TGF-beta receptor, FGF21, and alpha-Klotho to reverse aging-related phenotypes.
- supports Alpha-Klotho and FGF21 are natural soluble factors, whereas the TGF-beta receptor is naturally membrane-bound and required engineering into a soluble form for systemic delivery.
- supports Church's research group evaluated 45 different single gene therapies in rodents to select the subset of three factors for combination therapy.